Versant Venture Management, LLC
Follow13F filer, CIK 1560009, San Francisco, CA
Versant Venture Management, LLC reported $109,097,271 across 8 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-13.
Accepted , ingested 13F-HR 0001193125-26-460919
- Period
- 2026-09-30
- Reported value
- $109M
- Holdings
- 8
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 1
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| CTNMadded | +750,000 | $10.1M |
| SKYEnew | +250,962 | $404K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| SKYEexited | -2,007,704 | -$1.39M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001193125-26-460919, largest first. % of portfolio is the value over $109,097,271, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| GLUEMONTE ROSA THERAPEUTICS INC | 3,180,780 | $37.9M | 34.78% | 0 | Timeline | ||
| IPSCCENTURY THERAPEUTICS INC | 12,166,109 | $20.8M | 19.07% | 0 | Timeline | ||
| CTNMCONTINEUM THERAPEUTICS INC | 1,292,628 | $17.3M | 15.9% | +750,000 | Timeline | ||
| JBIOJADE BIOSCIENCES INC | 991,783 | $13.9M | 12.77% | 0 | Timeline | ||
| LENZLENZ THERAPEUTICS INC | 2,656,888 | $10.2M | 9.35% | 0 | Timeline | ||
| CRSPCRISPR THERAPEUTICS AG | 148,831 | $8.23M | 7.55% | 0 | Timeline | ||
| SKYESKYE BIOSCIENCE INC | 250,962 | $404K | 0.37% | new | Timeline | ||
| TEMPEST THERAPEUTICS INCTEMPEST THERAPEUTICS INC | 269,772 | $225K | 0.21% | 0 |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| SKYESKYE BIOSCIENCE INC | 2,007,704 | $1.39M | shares |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001193125-26-460919 | base | 2026-11-13 |